Ascendis Pharma A/S (ASND) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Ascendis Pharma A/S (ASND) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • 21 hours ago

Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference

COPENHAGEN, Denmark, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2026 key corporate milestones. Ascendis President and CEO Jan Mikkelsen will present this update on Monday, January 12, during the 44th Annual J.P.

GlobeNewsWire • Jan 9, 2026

Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia Transcript

Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia Transcript

Seeking Alpha • Jan 9, 2026

Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)

– Once-weekly TransCon ® CNP and TransCon ® hGH combination therapy showed durable growth without compromising safety or tolerability at 52 weeks – Annualized growth velocity (AGV) exceeded the 97th-percentile of average stature children – ACH height Z-score improvements indicated a tripling of efficacy compared to TransCon CNP monotherapy – Combination therapy demonstrated benefits beyond linear growth with improvements in body proportionality and arm span, aligning with the increase in linear growth – All children completed 52 weeks of treatment and remain on therapy in COACH as of today – Combination therapy was generally well tolerated, with generally mild treatment-emergent adverse events (TEAEs), consistent with TransCon CNP and TransCon hGH monotherapies – Ascendis to host conference call today at 4:30pm ET  COPENHAGEN, Denmark, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced topline results from Week 52 of COACH, the first Phase 2 clinical trial to evaluate combination therapy with once-weekly TransCon CNP (navepegritide) and once-weekly TransCon hGH (lonapegsomatropin) in children with achondroplasia. At Week 52, combination therapy showed durable growth without compromising safety or tolerability.

GlobeNewsWire • Jan 8, 2026

Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference

COPENHAGEN, Denmark, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in the 44th Annual J.P. Morgan Healthcare Conference and provide a business update on Monday, January 12, 2026, at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time in San Francisco, California.

GlobeNewsWire • Jan 5, 2026

Here's My Prediction For Who Could Acquire Ascendis Pharma

Ascendis Pharma is rated a cautious buy amid acquisition speculation, robust revenue growth, and a pivotal FDA decision on TransCon CNP. Yorvipath and Skytrofa drove Q3 revenues to €213.6 million, nearly quadrupling year-over-year, with operating profitability achieved for the quarter. TransCon CNP, targeting achondroplasia, faces a critical FDA PDUFA date on February 28th, with multi-billion-euro TAM potential if approved.

Seeking Alpha • Dec 15, 2025

Eight stock picks to play one of the healthiest corners of the market

The healthcare sector of the U.S. stock market as a whole is cheaply priced, which can make it attractive to investors concerned that the S&P 500 has gotten too expensive several years into a bull market.

Market Watch • Dec 11, 2025

High-Quality Compounders With Both Pricing Power And Idiosyncratic Growth

The Touchstone Mid Cap Growth Fund outperformed its benchmark, the Russell Midcap® Growth Index, for the quarter ended September 30, 2025. From a factor perspective, the Fund's overweight exposure to size was a relative tailwind to performance, offsetting a headwind from being underweight volatility. Consumer Discretionary was the largest source of relative gains.

Seeking Alpha • Dec 11, 2025

Final Trades: Ascendis Pharma, Monolithic Power, the IYC and the GPIQ

The Investment Committee give you their top stocks to watch for the second half.

CNBC Television • Dec 8, 2025

Ascendis: Q3 Results Validate The TransCon Platform

Ascendis Pharma has achieved operational profitability, driven by YORVIPATH's rapid adoption and strong Q3 2025 revenues of €213.6 million. ASND's robust cash position (€539 million) and self-sustaining business model eliminate near-term dilution risk and support continued pipeline investment. TransCon platform advances, including SKYTROFA label expansion and TransCon CNP, offer significant growth opportunities, with regulatory risk now mostly administrative.

Seeking Alpha • Dec 5, 2025